List view / Grid view
The drug’s developers reveal Keytruda increased progression-free survival (PFS) in…
The drug’s developers reveal Keytruda increased progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC) expressing PD-L1.
Merck expands Lambrolizumab clinical development program...
2 June 2013 | By Merck
Merck expands Lambrolizumab clinical development program...
Merck (NYSE: MRK), known as MSD outside the United States…
7 March 2013 | By Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role…
Amgen announced the submission of a supplemental Biologics License Application…
27 June 2011 | By Amgen
Amgen announced the submission of a supplemental Biologics License Application to the U.S. FDA to expand the indication for XGEVA® (denosumab)...
Amgen announced that the companies have entered into a definitive…
24 January 2011 | By Amgen
Amgen announced that the companies have entered into a definitive acquisition agreement under which Amgen is to acquire BioVex Group...
